Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I D R Arnott

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Alimentary Pharmacology & Therapeutics|June 26, 2003
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's diseaseI D R Arnott, G McNeill, J Satsangi
Alimentary Pharmacology & Therapeutics|April 23, 2002
Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?I D R Arnott, D Watts, S Ghosh
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 23, 2002
Whole gut lavage fluid interleukin-1beta and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remissionI D R Arnott, N Williams, H E Drummond, et al.
The British Journal of Surgery|February 22, 2002
Endoscopic ultrasonography in the diagnosis and management of suspected upper gastrointestinal submucosal tumoursE F Shen, I D R Arnott, J Plevris, et al.
Alimentary Pharmacology & Therapeutics|April 11, 2016
Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit dataR W Lynch, A M D Churchhouse, A Protheroe, et al.
Alimentary Pharmacology & Therapeutics|November 9, 2007
Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel diseaseC W Lees, A K Maan, B Hansoti, et al.
Alimentary Pharmacology & Therapeutics|July 18, 2006
The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohortG-T Ho, P Chiam, H Drummond, et al.
Gut|April 22, 2005
DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish populationC L Noble, E R Nimmo, H Drummond, et al.
Alimentary Pharmacology & Therapeutics|September 6, 2013
Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease auditR W Lynch, D Lowe, A Protheroe, et al.
Gut|June 13, 2003
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trialC S J Probert, S D Hearing, S Schreiber, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Alimentary Pharmacology & Therapeutics|June 26, 2003
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's diseaseI D R Arnott, G McNeill, J Satsangi
Alimentary Pharmacology & Therapeutics|April 23, 2002
Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?I D R Arnott, D Watts, S Ghosh
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 23, 2002
Whole gut lavage fluid interleukin-1beta and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remissionI D R Arnott, N Williams, H E Drummond, et al.
The British Journal of Surgery|February 22, 2002
Endoscopic ultrasonography in the diagnosis and management of suspected upper gastrointestinal submucosal tumoursE F Shen, I D R Arnott, J Plevris, et al.
Alimentary Pharmacology & Therapeutics|April 11, 2016
Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit dataR W Lynch, A M D Churchhouse, A Protheroe, et al.
Alimentary Pharmacology & Therapeutics|November 9, 2007
Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel diseaseC W Lees, A K Maan, B Hansoti, et al.
Alimentary Pharmacology & Therapeutics|July 18, 2006
The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohortG-T Ho, P Chiam, H Drummond, et al.
Gut|April 22, 2005
DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish populationC L Noble, E R Nimmo, H Drummond, et al.
Alimentary Pharmacology & Therapeutics|September 6, 2013
Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease auditR W Lynch, D Lowe, A Protheroe, et al.
Gut|June 13, 2003
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trialC S J Probert, S D Hearing, S Schreiber, et al.
Pageof 2